体外视网膜前膜模型与抗体通透性:与糖尿病黄斑水肿中抗VEGF耐药的关系
该研究回顾性分析接受抗VEGF治疗的糖尿病黄斑水肿(DME)患者临床资料,比较伴与不伴视网膜前膜(ERM)眼的差异,并用MIO-M1、ARPE-19和NTI-4细胞在Transwell膜上构建体外ERM模型评估抗体通透性。结果显示伴ERM的DME眼抗VEGF疗效降低,体外ERM模型以剂量依赖方式减少抗体通透性,提示ERM存在与抗VEGF耐药相关。
要点
- 伴ERM的DME眼首次抗VEGF后1个月CRT变化、12个月最终CRT和最终视力与不伴ERM眼显著不同。
- 体外ERM模型产生I型胶原,类似人ERM标本。
- 体外ERM模型下室荧光强度呈剂量依赖性显著降低。
核心结论
- 临床数据分析表明DME眼存在ERM会降低抗VEGF治疗效果。
- 体外ERM模型抗体通透性降低提示ERM存在与伴ERM的DME眼抗VEGF耐药相关。
研究设计与样本
- 回顾性分析接受抗VEGF治疗的DME患者临床资料,比较伴ERM与不伴ERM的DME眼临床差异。
- 使用MIO-M1、ARPE-19和NTI-4细胞在Transwell膜上构建体外ERM模型,用荧光标记抗体评估抗体通透性。
主要发现
- 伴ERM与不伴ERM的DME眼在首次抗VEGF治疗前与治疗后1个月间CRT变化、首次抗VEGF治疗后12个月最终CRT和最终视力上存在显著差异。
- 体外ERM模型产生I型胶原的方式与人ERM标本相似。
- 体外ERM模型下室的荧光强度呈剂量依赖性显著降低。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Diabetic macular edema (DME) is characterized by an accumulation of fluid in the macula due to diabetic retinopathy. Currently, anti-VEGF drugs are the standard treatment worldwide for DME. This study aimed to assess whether the existence of epiretinal membrane (ERM) affects anti-VEGF efficacy, due to reduced permeability of the antibody through the ERM. METHODS: We retrospectively examined clinical data of DME patients who underwent anti-VEGF treatment and evaluated whether clinical differences existed between DME eyes with ERM and those without ERM. We then created an in vitro ERM model using MIO-M1, ARPE-19, and NTI-4 cells on Transwell membranes and evaluated antibody permeability through this in vitro ERM model using fluorescently labeled antibodies. RESULTS: Central retinal thickness (CRT) change between before and 1 month after first anti-VEGF treatment, as well as final CRT and final visual acuity 12 months after first anti-VEGF treatment, significantly differed between DME eyes with ERM and those without ERM. The in vitro ERM model led to production of collagen I in a manner similar to that of human ERM specimens. Fluorescence intensity of the lower chamber of the in vitro ERM model was significantly reduced in a dose-dependent manner. CONCLUSIONS: Clinical data analysis indicated that the existence of ERM in DME eyes lowered the efficacy of anti-VEGF treatment. Reduced antibody permeability through the in vitro ERM model suggested ERM presence was associated with resistance to anti-VEGF treatment in DME eyes with ERM.
引用
- Namba R, Kaneko H, Suzumura A, et al. In Vitro Epiretinal Membrane Model and Antibody Permeability: Relationship With Anti-VEGF Resistance in Diabetic Macular Edema. Invest Ophthalmol Vis Sci. 2019. PMID: 31284311. doi:10.1167/iovs.19-26788
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。